Skip to Content
Get 14 Days Free
Sign Up
Sign In
Sign In
Learn
Start Investing
Investing Classroom
Investing Glossary
Plan
Tax Planning
Personal Finance
Save for College
Save for Retirement
Invest in Retirement
Research
Mutual Funds
Stocks
ETFs
Bonds
Best Investments
Portfolio
Markets
Investing
Learn
Start Investing
Investing Classroom
Investing Glossary
Plan
Tax Planning
Personal Finance
Save for College
Save for Retirement
Invest in Retirement
Research
Mutual Funds
Stocks
ETFs
Bonds
Best Investments
Portfolio
Markets
For Professionals
Research & Insights
Morningstar Blog
Featured Reports
Morningstar Magazine
The Investor Success Project
Morningstar Investment Conference
ESG Investing
Licensed Research
Software & Data Services
Morningstar Direct
Morningstar Office Cloud
Morningstar Advisor Workstation
Morningstar Data
PitchBook
Morningstar Enterprise Components
Money Management
Morningstar Retirement Manager
Morningstar Managed Portfolios
Morningstar Indexes
All Products & Services
Company
Who We Are
Work Here
Newsroom
Investor Relations
Global Contacts
Anthem Inc
ANTM
Morningstar Rating
Rating as of
Dec 10, 2019
Quote
Stock Analysis
News
Price vs Fair Value
Trailing Returns
Financials
Valuation
Operating Performance
Dividends
Ownership
Executive
Related
Sustainability Matters
5 Intriguing New Sustainable Funds
With more than a dozen open-end and exchange-traded offerings launched this year, we examine the ones to consider.
Stock Strategist Industry Reports
Investing With Our 2020 Healthcare Policy Outlook
We see risks for managed care but also opportunities to own moatworthy companies at sizable discounts.
Investing Specialists
Ultimate Stock-Pickers' Top 10 Buys and Sells
We see opportunity within the consumer cyclical sector.
Fund Spy
The 10 Biggest Funds to Get Upgrades in 2018
Funds from Vanguard, PIMCO, and T. Rowe Price are among the ratings boosts.
Premium Article
16 Overpriced Stocks With Eroding Moats
These narrow-moat stocks all have negative moat trends and are trading at 1- or 2-star levels.
Stock Strategist Industry Reports
Executive Orders Bring Uncertainty for Healthcare Exchanges
For now, we’re not changing our valuations or moat ratings for the affected companies.
Quarter-End Insights
Healthcare: Stock Selection Key as Valuations Rise
Valuations in the healthcare sector in aggregate look fair, increasing the importance on stock selection where innovation and redeployment of capital weigh heavily.
Fund Times
An Outstanding Large-Cap Fund for Patient Investors
Gold-rated Dodge & Cox Stock’s seasoned team, low fees, and decisive value approach have led to enviable long-term results.
Fund Times
This Global Fund Pays Off for Patient Investors
Silver-rated Oppenheimer Global fishes globally for growth ideas.
Fund Times
New Manager Off to Good Start at Popular Dividend Fund
John Linehan, manager of the Bronze-rated T. Rowe Price Equity Income, has generated fine results since taking over for the retiring Brian Rogers in late 2015.
Stock Strategist
Express Scripts Is One of the Most Powerful Players in Healthcare
The PBM has unparalleled supplier pricing power and scale advantages.
Quarter-End Insights
Healthcare: We See Value in the Drug and Biotech Industries
Overblown concerns over drug pricing in the U.S. are creating attractive valuations for the more innovative drug companies.
Fund Times
Stock Picks from Morningstar Analysts
A trio of Morningstar analysts share their outlooks for and opportunities in the healthcare, consumer, and basic materials sectors.
US Videos
Express Scripts: A Good Risk/Reward Tradeoff
Continued worries about Anthem’s lawsuit have created a buying opportunity in the pharmacy benefit manager, says Morningstar’s Matt Coffina.
Market Update
Can You Profit From the M&A Spree?
It's a record year for M&A deals in corporate America. Contributor John Waggoner explains what that means for investors.
Quarter-End Insights
Morningstar's Take on the Third Quarter
China fears and Fed uncertainty sent markets lower in the third quarter, but stocks still aren't cheap.
US Videos
Are Managed-Care Stocks Overvalued?
Consolidation activity in the sector will have a positive impact operationally, but the stocks are overpriced, says Morningstar's Vishnu Lekraj.
Commentary
Anthem/Cigna Merger Strategically Sound But Richly Priced
The combination should boost long-term economic profitability but Anthem is significantly overpaying for this transaction, writes Morningstar’s Vishnu Lekraj.
Credit Insights
Summer Slowdown Takes Hold in Secondary Markets, but Idiosyncratic Risk Remains
Curtain coming down on Greek tragedy.
Credit Insights
Deluge of New Issues Pressures Corporate Credit Spreads
New issue supply starting to overwhelm demand.
Sponsor Center